Literature DB >> 12947255

Morbidity with retroperitoneal procedures during endovascular abdominal aortic aneurysm repair.

W Anthony Lee1, Scott A Berceli, Thomas S Huber, C Keith Ozaki, Timothy C Flynn, James M Seeger.   

Abstract

PURPOSE: Retroperitoneal iliac procedures can enable successful endovascular repair of abdominal aortic aneurysm (AAA) in patients who otherwise would not be anatomically eligible. The purpose of this study was to determine perioperative outcome with adjunctive retroperitoneal procedures compared with standard bilateral femoral exposure.
METHODS: Between August 1997 and November 2002, 164 patients underwent elective endovascular AAA repair at a single university medical center. Anatomic, demographic, and early postoperative outcome data gathered prospectively were analyzed. Thirty-two patients (20%) underwent 38 separate adjunctive retroperitoneal procedures. Indications included small external iliac arteries (16 of 32 patients; 50%) and concomitant iliac aneurysm that precluded fixation of the endograft limbs in the common iliac arteries (16 of 32 patients; 50%). The 38 procedures consisted of 8 iliac conduits only, 14 iliac conduits with iliofemoral bypass grafts, and 16 hypogastric revascularization procedures. Data for the study patients were compared with data for 132 patients who underwent endovascular AAA repair through femoral incisions. Primary end points were hospital length of stay, and early morbidity and mortality.
RESULTS: Retroperitoneal procedures enabled an additional 14% of patients with AAA to undergo endovascular techniques. However, there was a significantly higher proportion of women and patients at high risk for anesthesia (American Society of Anesthesiologists class IV or higher) in the group who underwent retroperitoneal procedures. On average, retroperitoneal procedures were associated with 2.6-fold greater blood loss, 82% longer procedure time, 1.5 days additional hospital stay, and 1.8-fold higher rate of perioperative complications, compared with endovascular AAA repair with femoral exposure alone. In contrast, early mortality was similar in the two groups.
CONCLUSION: Adjunctive retroperitoneal procedures during endovascular AAA repair are associated with increased risk for complications and longer hospital length of stay, compared with AAA repair with standard femoral exposure only. They do not, however, increase early mortality, even in patients at high risk, and enable a larger subset of patients with AAA to undergo endovascular repair.

Entities:  

Mesh:

Year:  2003        PMID: 12947255     DOI: 10.1016/s0741-5214(03)00726-2

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  Endovascular Treatment of Abdominal Aortic Aneurysm with Complete Iliac Occlusion: Case Series and Literature Review.

Authors:  Randall W Franz; M Taha Ibrahim; Christopher F Tanga; David A Epstein
Journal:  Int J Angiol       Date:  2017-10-04

2.  Use of internal endoconduits as an adjunct to endovascular aneurysm repair in the setting of challenging aortoiliac anatomy.

Authors:  Timothy Wu; John G Carson; Christopher L Skelly
Journal:  Ann Vasc Surg       Date:  2009-09-11       Impact factor: 1.466

3.  Iliac anatomy and the incidence of adjunctive maneuvers during endovascular abdominal aortic aneurysm repair.

Authors:  Woo-Sung Yun; Kihyuk Park
Journal:  Ann Surg Treat Res       Date:  2015-05-14       Impact factor: 1.859

4.  Retroperitoneal iliac conduits as an alternative access site for endovascular aortic repair: a tertiary care center experience.

Authors:  Rajesh Vijayvergiya; Lipi Uppal; Ganesh Kasinadhuni; Prafull Sharma; Ashish Sharma; Ajay Savlania; Anupam Lal
Journal:  J Vasc Bras       Date:  2021-09-10

5.  Technical tips and procedural steps in endovascular aortic aneurysm repair with concomitant recanalization of iliac artery occlusions.

Authors:  Jorge Senkichi Uchiyamada; Shigeo Ichihashi; Shinichi Iwakoshi; Hirofumi Itoh; Nobuoki Tabayashi; Kimihiko Kichikawa
Journal:  Springerplus       Date:  2013-11-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.